Jenny Robertson - 15 Oct 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Signature
/s/ Youjin Choi, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
15 Oct 2025
Net transactions value
-$31,530
Form type
4
Filing time
17 Oct 2025, 19:28:53 UTC
Previous filing
20 Aug 2025
Next filing
20 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Robertson Jenny Chief Legal Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Youjin Choi, Attorney-in-Fact 17 Oct 2025 0001995009

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award $0 +9,900 +16% $0.000000 72,456 15 Oct 2025 Direct
transaction LXEO Common Stock Sale $31,147 -3,486 -4.8% $8.94 68,970 17 Oct 2025 Direct F1, F2
transaction LXEO Common Stock Sale $382 -40 -0.06% $9.56 68,930 17 Oct 2025 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs").
F2 This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 Includes 51,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.